Targets › PIK3CD
14 programs from 13 companies in 37 trials: 18 Phase 2, 16 Phase 1, 3 Phase 3; Oncology, Immunology, Other; next expected readout Nov 2026.
Phosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol (PI) and its phosphorylated derivatives at position 3 of the inositol ring to produce 3-phosphoinositides. Uses ATP and PtdIns(4,5)P2 (phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). (UniProt, O00329)
Open in Phaseline: the race on PIK3CD, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Pharming Technologies | Leniolisib PI3-kinase p110-delta subunit inhibitor | PIK3CD | Phase 3 | APDS; Primary Immunodeficiency Disorders (PIDs); PIDs Linked to PI3K | Nov 2026 |
| SecuraBio | Duvelisib PI3-kinase p110-delta subunit inhibitor; PI3-kinase p110-gamma subunit inhibitor | PIK3CD, PIK3CG | Phase 3 | Lymphoma; Newly Diagnosed Peripheral T-cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Recurrent Chronic Lymphocytic Leukemia … | Feb 2028 |
| Incyte | Parsaclisib PI3-kinase p110-delta subunit inhibitor | PIK3CD | Phase 2 | B-Cell Malignancies | Nov 2026 |
| National Cancer Institute (NCI) | Copanlisib Hydrochloride PI3-kinase p110-alpha subunit inhibitor; PI3-kinase p110-delta subunit inhibitor | PIK3CA, PIK3CD | Phase 2 | Advanced Lymphoma; Follicular Lymphoma; Malignant Solid Neoplasm; Advanced Malignant Solid Neoplasm … | Dec 2026 |
| Rhizen Pharmaceuticals | Tenalisib (RP6530) PI3-kinase p110-delta subunit inhibitor; PI3-kinase p110-gamma subunit inhibitor | PIK3CD, PIK3CG | Phase 2 | Triple Negative Breast Cancer (TNBC) | Dec 2026 |
| National Cancer Institute (NCI) | Umbralisib PI3-kinase p110-delta subunit inhibitor; Casein kinase I epsilon inhibitor; Tyrosine-protein kinase ABL inhibitor | PIK3CD, CSNK1E, ABL1 | Phase 2 | Grade 1 Follicular Lymphoma | Jan 2027 |
| City of Hope Medical Center | Umbralisib PI3-kinase p110-delta subunit inhibitor; Casein kinase I epsilon inhibitor; Tyrosine-protein kinase ABL inhibitor | PIK3CD, CSNK1E, ABL1 | Phase 2 | Mantle Cell Lymphoma | Jul 2027 |
| Christian Buske | Copanlisib PI3-kinase p110-alpha subunit inhibitor; PI3-kinase p110-delta subunit inhibitor | PIK3CA, PIK3CD | Phase 2 | Marginal Zone Lymphoma | Dec 2027 |
| Jennifer R. Brown, MD, PhD | Umbralisib PI3-kinase p110-delta subunit inhibitor; Casein kinase I epsilon inhibitor; Tyrosine-protein kinase ABL inhibitor | PIK3CD, CSNK1E, ABL1 | Phase 2 | Chronic Lymphocytic Leukemia | Jan 2028 |
| Kyowa Kirin | Zandelisib (ME-401) PI3-kinase p110-delta subunit inhibitor | PIK3CD | Phase 2 | Indolent B-cell Non-Hodgkin's Lymphoma | May 2028 |
| Incyte Biosciences Japan GK | parsaclisib PI3-kinase p110-delta subunit inhibitor | PIK3CD | Phase 1 | Non Hodgkins Lymphoma | Dec 2026 |
| Brown University | Copanlisib PI3-kinase p110-alpha subunit inhibitor; PI3-kinase p110-delta subunit inhibitor | PIK3CA, PIK3CD | Phase 1 | Metastatic Castration-resistant Prostate Cancer | Jan 2027 |
| University of Chicago | Umbralisib (TGR-1202) PI3-kinase p110-delta subunit inhibitor; Casein kinase I epsilon inhibitor; Tyrosine-protein kinase ABL inhibitor | PIK3CD, CSNK1E, ABL1 | Phase 1 | CLL | Dec 2027 |
| Dana-Farber Cancer Institute | Copanlisib PI3-kinase p110-alpha subunit inhibitor; PI3-kinase p110-delta subunit inhibitor | PIK3CA, PIK3CD | Phase 1 | Diffuse Large B Cell Lymphoma | – |
Chronic Lymphocytic Leukemia (2) APDS (2) Advanced Lymphoma (2) Advanced Malignant Solid Neoplasm (2) Lymphoma (2) Mantle Cell Lymphoma (1) Metastatic Castration-resistant Prostate Cancer (1) Non Hodgkins Lymphoma (1) Primary Immunodeficiency Disorders (PIDs) (1) PIDs Linked to PI3K (1) B-Cell Malignancies (1) Grade 1 Follicular Lymphoma (1)
mixed (7), small molecule (7)
National Cancer Institute (NCI) (2) City of Hope Medical Center (1) Brown University (1) Jennifer R. Brown, MD, PhD (1) Incyte Biosciences Japan GK (1) Pharming Technologies (1) Incyte (1) Christian Buske (1) Kyowa Kirin (1) Rhizen Pharmaceuticals (1) University of Chicago (1) SecuraBio (1) Dana-Farber Cancer Institute (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.